Reino Unido -
inglês -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alitretinoin 10mg capsules
alliance healthcare (distribution) ltd - alitretinoin - oral capsule - 10mg
Reino Unido -
inglês -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alitretinoin 30mg capsules
alliance healthcare (distribution) ltd - alitretinoin - oral capsule - 30mg
Canadá -
inglês -
Health Canada
toctino capsule
glaxosmithkline inc - alitretinoin - capsule - 10mg - alitretinoin 10mg - misc. skin and mucous membrane agents
Canadá -
inglês -
Health Canada
toctino capsule
glaxosmithkline inc - alitretinoin - capsule - 30mg - alitretinoin 30mg - misc. skin and mucous membrane agents
Canadá -
inglês -
Health Canada
hanzema capsule
dr. reddy's laboratories inc - alitretinoin - capsule - 10mg - alitretinoin 10mg - misc. skin and mucous membrane agents
Canadá -
inglês -
Health Canada
hanzema capsule
dr. reddy's laboratories inc - alitretinoin - capsule - 30mg - alitretinoin 30mg - misc. skin and mucous membrane agents
Estados Unidos -
inglês -
NLM (National Library of Medicine)
panretin- alitretinoin gel
concordia pharmaceuticals inc. - alitretinoin (unii: 1ua8e65kdz) (alitretinoin - unii:1ua8e65kdz) - panretin® gel is indicated for topical treatment of cutaneous lesions in patients with aids-related kaposi’s sarcoma. panretin® gel is not indicated when systemic anti-ks therapy is required (e.g., more than 10 new ks lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary ks, or symptomatic visceral involvement). there is no experience to date using panretin® gel with systemic anti-ks treatment. panretin® gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.
Reino Unido -
inglês -
MHRA (Medicines & Healthcare Products Regulatory Agency)
toctino 10mg capsules
stiefel laboratories (uk) ltd - alitretinoin - oral capsule - 10mg
Reino Unido -
inglês -
MHRA (Medicines & Healthcare Products Regulatory Agency)
toctino 30mg capsules
stiefel laboratories (uk) ltd - alitretinoin - oral capsule - 30mg
União Europeia -
inglês -
EMA (European Medicines Agency)
panretin
eisai gmbh - alitretinoin - sarcoma, kaposi - antineoplastic agents - panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (aids)-related kaposi's sarcoma (ks) when:lesions are not ulcerated or lymphoedematous, and;treatment of visceral ks is not required, and;lesions are not responding to systemic antiretroviral therapy, and;radiotherapy or chemotherapy are not appropriate.